Patents by Inventor Kim Suzanne Midwood

Kim Suzanne Midwood has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT FOR DUPUYTREN'S DISEASE
    Publication number: 20160280775
    Abstract: Musculoskeletal fibroproliferative disorders, such as Dupuytren's disease may be treated by administering locally a TNF-? antagonist. TNF-? antagonists find particular utility in inhibiting the progression of early disease state Dupuytren's disease and other musculoskeletal fibroproliferative disorders and, in combination with extracellular matrix degradation agents (such as collagenase or matrix metalloproteinase I), treating advanced disease state Dupuytren's disease and, in particular inhibiting recurrence.
    Type: Application
    Filed: September 11, 2015
    Publication date: September 29, 2016
    Applicant: ISIS Innovation Limited
    Inventors: Jagdeep Nanchahal, Kim Suzanne Midwood
  • Biological Materials and Uses Thereof
    Publication number: 20160039919
    Abstract: There is provided agents for modulation of a chronic inflammatory response wherein the agent modulates the biological activity of tenascin-C. There is also provided methods of identifying agents modulating tenascin-C and chronic inflammation. There are also provided uses of such agents.
    Type: Application
    Filed: July 22, 2015
    Publication date: February 11, 2016
    Inventors: Kim Suzanne Midwood, Brian Maurice John Foxwell
  • Treatment for dupuytren's disease
    Patent number: 9138458
    Abstract: Musculoskeletal fibroproliferative disorders, such as Dupuytren's disease may be treated by administering locally a TNF-? antagonist. TNF-? antagonists find particular utility in inhibiting the progression of early disease state Dupuytren's disease and other musculoskeletal fibroproliferative disorders and, in combination with extracellular matrix degradation agents (such ascollagenase or matrix metalloproteinase I), treating advanced disease state Dupuytren's disease and, in particular inhibiting recurrence.
    Type: Grant
    Filed: October 31, 2011
    Date of Patent: September 22, 2015
    Assignee: Isis Innovation Limited
    Inventors: Jagdeep Nanchahal, Kim Suzanne Midwood
  • TENASCIN-C AND USE THEREOF IN RHEUMATOID ARTHRITIS
    Publication number: 20140322211
    Abstract: The present invention provides a method of determining the rheumatoid arthritis status of a subject, or the progression of rheumatoid arthritis, or the appropriate treatment for a subject with rheumatoid arthritis, comprising the steps of (a) determining the level of tenascin-C in a sample from said subject; and (b) comparing the level of tenascin-C determined in step (a) with one or more reference values. Preferably the rheumatoid arthritis referred to is erosive rheumatoid arthritis. The be accompanied when published by FIG. 5.
    Type: Application
    Filed: December 12, 2012
    Publication date: October 30, 2014
    Inventor: Kim Suzanne Midwood
  • TREATMENT FOR DUPUYTREN'S DISEASE
    Publication number: 20130287760
    Abstract: Musculoskeletal fibroproliferative disorders, such as Dupuytren's disease may be treated by administering locally a TNF-? antagonist. TNF-? antagonists find particular utility in inhibiting the progression of early disease state Dupuytren's disease and other musculoskeletal fibroproliferative disorders and, in combination with extracellular matrix degradation agents (such ascollagenase or matrix metalloproteinase I), treating advanced disease state Dupuytren's disease and, in particular inhibiting recurrence.
    Type: Application
    Filed: October 31, 2011
    Publication date: October 31, 2013
    Applicant: ISIS INNOVATION LIMITED
    Inventors: Jagdeep Nanchahal, Kim Suzanne Midwood
  • Biological Materials and Uses Thereof
    Publication number: 20130045212
    Abstract: There is provided agents for modulation of a chronic inflammatory response wherein the agent modulates the biological activity of tenascin-C. There is also provided methods of identifying agents modulating tenascin-C and chronic inflammation. There are also provided uses of such agents.
    Type: Application
    Filed: March 15, 2010
    Publication date: February 21, 2013
    Inventors: Kim Suzanne Midwood, Brian Maurice John Foxwell, Karen Foxwell